{"schema_version":"secwatch.filing_event.v1","accession":"0001077183-26-000022","form_type":"8-K","ticker":"NEO","cik":"0001077183","company_name":"NEOGENOMICS INC","filed_at":"2026-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:31.917523+00:00","generated_at":"2026-05-15T02:41:48.819413+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"NeoGenomics Q1 revenue up 11% to $187M; raises FY2026 guidance to $797-803M","bullets":["Consolidated revenue $187M (+11% YoY); Clinical revenue +14%, NGS +26%.","Net loss narrowed 34% to $17M; adjusted EBITDA $9M (+27% YoY).","Raised FY2026 revenue guidance to $797-803M (prior range not specified).","Launched RaDaR ST MRD assay; received MolDX coverage for PanTracer LBx.","Cash and marketable securities $146M at quarter end."],"urls":{"canonical":"https://secwatch.observer/filing/0001077183-26-000022","json":"https://secwatch.observer/filing/0001077183-26-000022.json","markdown":"https://secwatch.observer/filing/0001077183-26-000022.md","text":"https://secwatch.observer/filing/0001077183-26-000022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1077183/000107718326000022/0001077183-26-000022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1077183/000107718326000022/neo-20260428.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T02:41:48.819413+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9be15aa1cfe2d86b4055403dfbe900a61d75e0c4","claim":"NEOGENOMICS INC reported first quarter of 2026 results: revenue $187 million, net income $17 million. Guidance raised.","evidence_excerpt":"Consolidated revenue for the first quarter of 2026 was $187 million, an increase of 11% over the same period in 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718326000022/0001077183-26-000022-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2026"},{"label":"Revenue","value":"$187 million"},{"label":"Net income","value":"$17 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"d3f817a1ec98cf5b8c93963156ea60ea4676925a","claim":"NEOGENOMICS INC reported full-year 2026 results: revenue $797-$803 million. Guidance raised.","evidence_excerpt":"Company announces increase in full-year 2026 revenue guidance to a range of $797-$803 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718326000022/0001077183-26-000022-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full-year 2026"},{"label":"Revenue","value":"$797-$803 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}